POSTER SESSION III
Tuesday, March 23, 2010   —  9:30 AM - 12:00 Noon
Exhibit Hall


Click on the blue numbers in parentheses to display abstracts.
Click the button next to any title to add to Itinerary Planner...


BREAST PATHOLOGY



Poster#Title and AuthorsItinerary
Planner
31 Cross-Sectional Study of Breast Cancer among Hispanic Women Living in the United States (283)
ER Parrilla-Castellar, D Carter, MJ Merino - National Institutes of Health, Bethesda, MD 		Add
32 Clinicopathologic Characteristics and Molecular Subtypes of Breast Cancers in Young Women (271)
HD Morris, E King, Y Peng, VR Sarode - University of Texas Southwestern Medical Center, Dallas, TX 		Add
33 Demographics and Tumor Characteristics of Breast Cancer in Young Women: Evidence of Racial Disparity (242)
C Kinonen, KP Siziopikou - Rush University Medical Center, Chicago, IL; Northwestern University Medical Center, Chicago, IL 		Add
34 Breast Cancer in African Women (155)
C Bewtra - Creighton University Medical Center, Omaha, NE 		Add
35 Histologic and Epigenetic Characterization of Pre- and Postmenopausal Breast Cancer from Women in Senegal, West Africa (294)
M Rendi, KH Allison, P Sow, P Toure, A Dem, S Hawes, Q Feng, N Kiviat - Univ of Washington, Seattle 		Add
36 Demographic, Clinical and Radiological Factors in Ductal Carcinoma In Situ of the Breast in Different Ethnic Groups: An Analysis of 75 Cases (319)
RT Stapp, A Raghunathan, A Stark, DA Chitale - Henry Ford Health System, Detroit, MI 		Add
37 Contralateral Prophylactic Sentinel Lymph Node Biopsy for Breast Carcinoma: Too Much Dissection for Too Little Gain? (211)
J Hart, M Fiel-Gan, E Brady, R Ringer, A Ricci, Jr - Hartford Hospital, Hartford, CT 		Add
38 Molecular Analysis Evaluation of Axillary Nodal Micrometastasis in Patients with Breast Cancer (159)
SB Bokhari, AH Uihlein, KM Jasnosz, SD Finkelstein, JF Silverman - Allegheny General Hospital, Pittsburgh, PA; RedPath Integrated Pathology, Pittsburgh, PA 		Add
39 Microinvasive Lobular Carcinoma of Breast: Characterization of a Rare Entity Based on a Clinicopathological Profile of Fifteen Cases (299)
DS Ross, SA Hoda - Weill Cornell Medical College, New York 		Add
40 Do True Mixed Invasive Ductal and Lobular Carcinomas of the Breast Exist? (213)
A Heimann, C Tornos, Z Schreiber, P Kane, S Liang, B O'Hea, M Singh, J Liu - Stony Brook University Medical Center, Stony Brook, NY 		Add
41 Transmembrane Protein E-Cadherin May Not Be Necessary for Duct Formation in Breast Carcinomas (255)
J Liu, A Heimann, M Singh, Z Schreiber, Y Hu, B O'Hea, C Tornos - Stony Brook University Medical Center, Stony Brook, NY 		Add
42 Lobular Carcinoma Progression Model: Immunohistochemical Analysis on Tissue Microarray (166)
F Chen, J Cangiarella, L Chiriboga, F Darvishian - NYU-Langone Medical Center, New York, NY 		Add
43 Florid Lobular Carcinoma In-Situ: Molecular Profiling and Comparison to Classic LCIS and Pleomorphic LCIS (313)
SJ Shin, PP Rosen, A Lal, S DeVries, J Suzuki, R Roy, E Hwang, SJ Schnitt, F Waldman, YY Chen - Weill Cornell Med College, NY, NY; UCSF, San Francisco, CA; Beth Israel Deaconess Med Ctr, Boston, MA 		Add
44 Neuroendocrine Ductal Carcinoma In Situ of the Breast - A Distinct Variant of DCIS (237)
T Kawasaki, G Sakamoto, T Kondo, T Nakazawa, T Yamane, K Mochizuki, D Niu, D Ma, Y Ishii, M Inoue, S Inoue, H Tsunoda-shimizu, S Nakamura, R Katoh - University of Yamanashi, Yamanashi, Japan 		Add
45 Correlation of COX-2 Expression with Estrogen Receptor Status in DCIS (222)
Y Hussein, S Bandyopadhyay, S Madan, T Jazaerly, K Hayek, B Albashiti, M Ibrahim, I Khalifeh, W Sakr, R Ali-Fehmi - Wayne State University, Detroit; American University of Beirut, Beirut, Lebanon 		Add
46 High Expression of EIG121 Identifies Women with Triple Negative Breast Cancer with a Better Prognosis (185)
L Deng, B Hennessy, R Broaddus - MD Anderson Cancer Center, Houston, TX 		Add
47 Triple Negative Breast Cancers: Outcome Correlation with Immunohistochemical Expression of Basal Markers (326)
PH Tan, A Thike, PY Cheok - Singapore General Hospital, Singapore, Singapore 		Add
48 Triple-Negative Breast Cancers: Different Sensitivity to Chemotheray (173)
YL Choi, E Oh, Y Kim, YH Park, EY Cho, JE Lee, JH Kim, SJ Nam, YH Lim, JH Yang, YK Shin, YC Hong - Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University College of Pharmacy, Seoul, Korea; National Cancer Center, Goyang, Korea; Seoul National University College of Medicine, Seoul, Korea 		Add
49 Analysis of Osteopontin Expression in HER2-Positive and Basal/Triple Negative Breast Carcinomas (136)
E Alcaraz, M Planelles, D Giner, L Sanchez-Tejada, T Muci, FI Aranda, G Peiro - Hospital General Universitari, Alacant, Spain 		Add
50 Tissue Factor Expression in Triple-Negative Breast Carcinomas (350)
XM Zhang, CM Schneider, A Padmanabhan, R Sterling, ME Bromberg - Temple University, Philadelphia, PA 		Add
51 Morphology and Immunophenotype of Ductal Carcinoma In Situ in Triple Negative Breast Cancer (340)
YH Wen, M Akram, T Nehhozina, H Mohammed, L Norton, E Brogi - Memorial Sloan-Kettering Cancer Center, New York, NY 		Add
52 Triple-Negative Phenotype and/or High Mitotic Rate May Improve Selection of High-Risk Patients for BRCA Testing (251)
TR Lester, BK Arun, A Gutierrez Barrera, L Huo, CT Albarracin, MZ Gilcrease - MD Anderson Cancer Center, Houston, TX 		Add
53 Differences in AKT Pathway Detected by Digital Quantification of Protein Expression in Different Subtypes of Breast Cancer (161)
JVS Carniello, RM Rocha, FA Soares, VP Andrade - AC Camargo Cancer Hospital, Sao Paulo, SP, Brazil 		Add
54 Prognostic Factors in Triple Negative Breast Carcinomas: Is Sub-Classification Using Basal Markers Warranted? (279)
MJ Nystrom, ES Hwang, A Griffin, W Devine, A Lal, I Mehdi, S DeVries, F Waldman, JT Rabban, YY Chen - University of California, San Francisco, SF, CA 		Add
55 Melatonin Receptor in Triple Negative Breast Carcinoma in African-American Women (281)
GM Oprea-Ilies, E Haus, LL Sackett-Lundeen, D Lawson, C Cohen - Emory University, Atlanta, GA; University of Minnesota, Minneapolis, MN; Regions Hospital, St Paul, MN 		Add
56 Expression of Breast Specific Markers in Triple-Negative Breast Carcinomas (278)
MJ Nystrom, ES Hwang, A Lal, I Mehdi, JT Rabban, YY Chen - University of California, San Francisco, San Francisco, CA 		Add
57 DNA Damage-Associated Proteins in Triple Negative Breast Cancers (207)
G Guler, C Himmetoglu, RE Jimenez, WP Wang, S Costinean, D Suren, M Hayran, C Shapiro, K Huebner - Hacettepe University, Ankara, Turkey; Ataturk Research and Education Hospital, Ankara, Turkey; Mayo Clinic, Rochester, MN; VA Medical Center at Baltimore, Baltimore, MD; The Ohio States University Medical Center, Columbus, OH 		Add
58 Gene Expression Signature as a Predictor for Trastuzumab Resistance in Breast Carcinoma with Amplified HER2 (239)
T Khoury, K Kanehira, D Wang, F Ademuyiwa, S Liu - Roswell Park Cancer Inst, Buffalo 		Add
59 Semi-Quantitative Estrogen Receptor Expression Level Influences Response to Trastuzumab Containing Neo-Adjuvant Chemotherapy in HER2 Positive Tumors (156)
R Bhargava, DJ Dabbs, S Beriwal, RR Johnson, AM Brufsky, B Lembersky, A Soran, GM Ahrendt - Magee-Womens Hospital of UPMC, Pittsburgh, PA 		Add
60 Breast Cancer Molecular Subtypes Treated with Neoadjuvant Chemotherapy: Correlation with Grade, Ploidy, Ki67 and p53 Expression (174)
A Cockburn, J Han, D Euhus, Y Peng, VR Sarode - UTSW, Dallas, TX 		Add
61 Integration of Microarray CGH and Expression Analysis Reveals Potential Breast Cancer Therapeutic Targets (272)
A Muggerud, H Horlings, MB Lambros, R Natrajan, A Mackay, A Ashworth, MJ van de Vijver, JS Reis-Filho - ICR, London, United Kingdom; Academic Medical Center, Amsterdam, Netherlands 		Add
62 Expression of Transcription Factors [FOXA1, GATA-3] in Estrogen Receptor Negative and Progesterone Receptor Positive Groups: A Single Hormone Receptor Subset Analysis (233)
DF Jones, G Carter, D Gingell, K McManus, M Chivukula - Magee Womens Hospital of UPMC, Pittsburgh, PA 		Add
63 Role of Transcription Factors [FOXA1, GATA-3] in Predicting Outcome in ER+ and ER- and Ductal Carcinoma-In-Situ Patients with and without Invasive Carcinoma: A Retrospective Subset Analysis (286)
J Picarsic, A Brufsky, G Ahrendt, A Onisko, M Chivukula - Magee Women's Hospital of UPMC, Pittsburgh, PA; UPMC Cancer Institute, Pittsburgh, PA 		Add
64 Cancer/Testis (CT) Antigens Are Preferentially Expressed in Hormone Receptor Negative Breast Cancers and May Offer Therapeutic Targets (300)
DS Ross, O Caballero, P Lee, E Riedel, SA Hoda, LJ Old, AM Neville, Y-T Chen - Weill Cornell Medical College, New York; Ludwig Institute for Cancer Research, New York; Memorial Sloan-Kettering Cancer Center, New York 		Add
65 mTOR Immunohistochemical Expression is of Prognostic Relevance in High Risk Breast Carcinoma (160)
E Bragantini, F Mauri, C Cantaloni, D Aldovini, M Bonzanini, A Ferro, E Galligioni, F Buttitta, A Marchetti, L Cuorvo, P Dalla Palma, M Barbareschi - S Chiara Hospital, Trento, Italy; Imperial College London, Hammersmith Hospitals, London, United Kingdom; University Gabriele D'Annunzio, Chieti, Italy 		Add
66 The Role of EGFR and IGF1R in MAPK and PI3K/Akt Signaling Pathways in HER2-Positive Breast Carcinoma (285)
G Peiro, M Planelles, FI Aranda, E Adrover, L Sanchez-Tejada, D Giner, FJ Gutierrez-Avino, E Lerma - Hospital General Universitari, Alacant, Spain; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain 		Add